Company Filing History:
Years Active: 2017-2022
Title: **Innovative Contributions of Inventor Cindy Luongo**
Introduction
Cindy Luongo, an innovative inventor based in Bethesda, MD, has made significant strides in the field of virology. With a total of five patents to her name, Luongo's work focuses on developing recombinant respiratory syncytial virus (RSV) strains that hold promise for future vaccine development. Her research is critical in addressing respiratory diseases, particularly in vulnerable populations such as young children and the elderly.
Latest Patents
Among Luongo's most notable patents are her two latest innovations. The first is titled **"Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes."** This patent discloses novel recombinant RSVs containing mutations in the M2-2 open reading frame that hinder the expression of the M2-2 protein. The mutations can be further combined with alterations in other genetic loci to tailor the level of attenuation. These recombinant RSV strains have potential applications as live-attenuated vaccines.
The second patent is entitled **"Genetically stable live attenuated respiratory syncytial virus vaccine and its production."** This patent details recombinant RSVs designed with specific mutations that enhance genetic and phenotypic stability, making them attractive candidates for vaccine development. The patent includes polynucleotide sequences and methodologies for producing these viruses, providing a roadmap for their potential use in immunization.
Career Highlights
Cindy Luongo's career has been marked by a commitment to advancing the field of respiratory virus research. Her patents demonstrate her innovative approach to creating safer and more effective vaccine candidates. Working with the **United States of America As Represented by the Secretary of the Department of Health and Human Services**, Luongo has contributed her expertise to significant public health initiatives.
Collaborations
Throughout her career, Luongo has collaborated with esteemed colleagues, including Peter L Collins and Ursula J Buchholz. These partnerships have fostered a dynamic research environment that encourages the exchange of ideas and expertise, further enriching her contributions to the scientific community.
Conclusion
Cindy Luongo's innovations in the development of recombinant RSV vaccines signify a promising advancement in respiratory disease prevention. Her dedication to research and collaboration highlights her importance in the realm of virology. With her continuing work, Luongo remains a key player in the quest for effective vaccines, ultimately aiming to improve public health outcomes.